The AI Dilemma in BioPharma: Five Counter-Intuitive Truths QA and Executive Leadership Must Know

AI in pharma is not just an IT project

Corporate boards are pushing IT, Quality Assurance, and operations teams to deploy artificial intelligence quickly. The problem is that most pharmaceutical IT environments were never designed for AI.

They were designed to control data, restrict access, maintain validated states, preserve audit trails, and keep regulated systems appropriately segregated. That creates an unusual tension.

Leadership wants speed, efficiency, lower costs, and automation. Quality needs traceability, validated processes, reliable data, human accountability, and defensible decision-making.

The answer is not to avoid AI. It is to recognize that deploying AI inside a GxP environment is not simply a software decision. It is a quality and regulatory control decision. Five issues deserve particular attention.

1. The boardroom AI mandate can collide with GMP reality

For years, pharmaceutical companies have built highly controlled technology environments around requirements such as 21 CFR Part 11, EU Annex 11, data integrity, system access controls, and validated computerized systems.

Those controls were necessary. But they also created large amounts of operational information across separate systems. An executed batch record may be on paper. Laboratory data may sit in LIMS. Manufacturing information may be in MES. Deviations live in an eQMS. Equipment information may be somewhere else entirely.

Each system can function exactly as intended while QA still spends hours assembling the evidence needed to make one quality decision. That is why AI cannot simply be dropped into a GMP process and treated like a productivity application. The architecture must preserve source evidence, access controls, traceability, data provenance, validation, and appropriate human oversight.

2. Not every AI model belongs in a critical GMP decision

Europe's proposed Annex 22 provides an important look at where AI regulation may be heading. The draft draws a significant distinction between AI that assists a regulated process and AI that directly makes a critical GMP decision.

Static models with controlled parameters are much easier to qualify and validate because their behavior can be tested and reproduced. Generative AI and other probabilistic systems create a different challenge. The same prompt may not always generate exactly the same response. Models may hallucinate. Outputs can depend on context, model configuration, source material, and other variables.

That does not make generative AI unusable in pharma. It means context of use matters. AI may be extremely valuable for finding information, organizing evidence, identifying potential anomalies, summarizing records, or helping a reviewer determine where attention is needed.

But the closer the system gets to independently deciding whether a batch should be released, whether an OOS is scientifically justified, or whether a critical GMP requirement has been satisfied, the higher the validation and governance burden becomes. Human accountability does not disappear because the underlying technology becomes more sophisticated.

3. You may not need to digitize everything first

One of the largest misconceptions around pharmaceutical AI is that companies must first complete a massive digital transformation. That often means replacing paper systems, installing MES, modernizing LIMS, integrating ERP, restructuring the QMS, and connecting years of legacy data before meaningful AI can be deployed. For large organizations, those programs can take years. Meanwhile, QA continues reviewing paper and electronic records manually.

There is another model. Instead of replacing the underlying manufacturing infrastructure, an evidence layer can operate across existing records and systems. Paper batch records can be digitized. Scanned PDFs can be interpreted. Information can be pulled from existing systems. Automated verification can then identify exceptions requiring human attention while preserving the original source evidence.

The objective is not necessarily to replace the system of record. It is to make the information already being generated by the manufacturing operation more usable. This approach is particularly interesting for older pharmaceutical facilities, CDMOs, API manufacturers, and companies operating hybrid paper/electronic environments where a complete infrastructure replacement may not be economically practical.

4. Audit trail review should become a signal, not a chore

FDA has been clear for years that electronic data must be reliable and accurate and that manufacturers need meaningful controls for detecting and preventing data integrity problems. Yet audit trail review can still become a largely manual exercise. Thousands of system events may be reviewed even though only a small percentage represent meaningful quality risk.

A better model is review by exception. Before batch disposition, automated tools could identify events such as:

• Repeated testing
• Aborted analytical runs
• Deleted data
• Manual integrations
• Modified processing parameters
• Changes made after initial acquisition
• Missing reasons for changes
• Unusual user activity
• Unexpected changes to sample sequences

QA could then focus its attention on the events that actually require investigation. The same information can also be trended across time. One unusual event may be explainable. Repeated events involving the same analyst, instrument, process, product, or department may reveal something much more important. That turns the audit trail from a compliance record into a quality intelligence signal.

5. Your most valuable AI asset may already exist

The most interesting concept may be what Litewave AI describes as Manufacturing Memory. A pharmaceutical facility creates an enormous institutional memory over its lifetime. It exists in executed batch records, deviations, CAPAs, analytical data, investigations, equipment records, supplier information, complaints, environmental monitoring, and countless other quality records.

Traditionally, much of that information becomes difficult to use once the immediate batch, deviation, or investigation is closed. The next investigation begins and someone asks: "Have we seen this before?" The answer may exist somewhere across millions of pages of historical records.

AI changes the economics of accessing that information. Instead of simply searching individual documents, modern evidence platforms can begin connecting historical events, identifying similar deviations, comparing batch performance, locating recurring signals, and placing current quality events in the context of years of manufacturing history.

That accumulated operational knowledge may ultimately become more valuable than the AI model itself. Models will continue to improve. Your manufacturing history belongs to you.

What this could mean for QA

The objective should not be to remove QA from pharmaceutical decision-making. It should be to remove the low-value work surrounding the decision. QA professionals should spend their time evaluating risk, investigating meaningful anomalies, challenging conclusions, understanding processes, and protecting patients. They should not spend hours manually locating values scattered across hundreds of pages because no one has provided them with a better tool.

Real-world deployments are beginning to demonstrate what this model can look like. Litewave reports that one API manufacturer reduced hands-on batch disposition review from days to hours using an evidence layer over existing paper-based processes without replacing the underlying manufacturing infrastructure. Another pharmaceutical CMO implemented automated verification across more than 200 operations per batch, with each identified issue traceable back to the underlying source record.

Those examples point toward a different vision of digital transformation. Instead of asking "How do we replace every legacy system?" leadership may want to start asking "How do we make the evidence inside our existing systems usable right now?"

The bigger question for executive leadership

AI adoption in pharmaceutical manufacturing does not require choosing between innovation and compliance. But it does require understanding what problem the technology is actually solving. Installing another enterprise system does not automatically improve quality. Digitizing a paper process does not automatically make the process smarter. And putting a large language model on top of poor-quality information does not suddenly create reliable GMP evidence.

The strongest AI strategies will likely combine three things:

Reliable source data. Controlled technology. Qualified human decision-making.

The organizations that get this right may find that AI does more than accelerate individual tasks. It can help transform years of fragmented manufacturing records into an active quality intelligence system. And that could fundamentally change how QA reviews batches, investigates deviations, identifies trends, and prepares for regulatory scrutiny.